New Once-Daily pill could simplify CAH treatment
NCT ID NCT03760835
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a once-daily dual-release hydrocortisone pill (Plenadren) works better than standard multiple-dose glucocorticoids for adults with congenital adrenal hyperplasia. The trial will enroll 150 adults and measure changes in cholesterol, blood sugar, weight, blood pressure, and quality of life. The goal is to see if the simpler dosing schedule improves health outcomes and daily living.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dual-release hydrocortisone (Plenadren)
- What this could lead to
- If it works, this could offer a more convenient once-daily treatment option that improves cholesterol, blood sugar, and quality of life for people with congenital adrenal hyperplasia.
- What could go wrong
- This is a Phase 4 open-label study, so results may be influenced by participants knowing which treatment they receive. The improvement over standard therapy may be modest, and not all patients may respond well.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Federico II University
RECRUITINGNaples, 80131, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple saliva test replace blood draws for hormone monitoring?
- New program aims to smooth healthcare transition for teens with rare hormone disorder
- New hope for CAH: drug may slash steroid use
- New hope for toddlers with rare hormone disorder?
- Italian study checks how well newborn screening detects rare hormone disorder
- New hormone treatment shows promise for rare adrenal disorder